J
Julie M. Vose
Researcher at University of Nebraska Medical Center
Publications - 569
Citations - 51589
Julie M. Vose is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 97, co-authored 541 publications receiving 46915 citations. Previous affiliations of Julie M. Vose include Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review
Theresa Hahn,Steven N. Wolff,Myron S. Czuczman,Richard I. Fisher,Hillard M. Lazarus,Julie M. Vose,Lisa Warren,Richard Watt,Philip L. McCartby +8 more
TL;DR: The search used the MeSH term 'Non-Hodgkin's lymphoma', limited to 'Drug Therapy' or 'Therapy', and the National Institute of Health NLM website were searched for studies published in English between January 1980 and December 2000.
Journal Article
Adult Burkitt lymphoma: advances in diagnosis and treatment.
Ibrahim Aldoss,Dennis D. Weisenburger,Kai Fu,Wing C. Chan,Julie M. Vose,Philip J. Bierman,R. Gregory Bociek,James O. Armitage +7 more
TL;DR: Burkitt lymphoma in adults cannot be treated effectively with the common regimens used for diffuse large B-cell lymphoma such as CHOP-R, so prompt diagnosis and initiation of appropriate therapy with attention to the possibility of tumor lysis syndrome are necessary for optimal results.
Journal ArticleDOI
Peripheral T-Cell Non-Hodgkin's Lymphoma
TL;DR: T-cell non-Hodgkin's lymphoma (T-NHL) are uncommon malignancies accounting for 10% to 15% of all NHL, but the geographic variation may reflect exposure to specific pathogenic viruses in Asian countries.
Journal ArticleDOI
Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies.
TL;DR: Overall, the patients had a positive outlook after high‐dose therapy and transplantation, with most being able to return to work and enjoy a normal life style, and up to one‐third of the patients reported changes in sexual function or desire.
Journal ArticleDOI
Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
Julie M. Vose,Douglas Rizzo,Jing Tao-Wu,James O. Armitage,Asad Bashey,Linda J. Burns,N. P. Christiansen,Cesar O. Freytes,Robert Peter Gale,John Gibson,Sergio Giralt,Roger H. Herzig,Charles F. LeMaistre,Philip L. McCarthy,Stephen D. Nimer,Finn Bo Petersen,David P. Schenkein,Peter H. Wiernik,Joseph Wiley,Fausto R. Loberiza,Hillard M. Lazarus,Koen van Biesen,Mary M. Horowitz +22 more
TL;DR: In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age >or=40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival.